We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 610

ACCC conditionally clears NestlePfizer deal
  • Herbert Smith Freehills LLP
  • Australia
  • November 30 2012

On 22 November 2012, the Australian Competition and Consumer Commission (ACCC) announced it would not oppose the proposal by Nestlé SA to acquire the global infant nutrition business of Pfizer Inc (the transaction), subject to court enforceable undertakings

BaxterGambro gets ACCC tick of approval
  • King & Wood Mallesons
  • Australia
  • September 5 2013

Adding to the regulatory approvals in China (blogged about in our previous post), New Zealand and Europe, the ACCC has announced that it will not

Interim authorisation granted to eRx script
  • Gilbert + Tobin
  • Australia
  • February 28 2013

The ACCC granted interim authorisation to eRx Script Exchange to allow it to enter into a contract with MediSecure to facilitate interoperability

The competition and IP intersect
  • King & Wood Mallesons
  • Australia
  • February 13 2014

In a move which will be closely watched by the pharmaceutical industry, the ACCC has commenced proceedings against Pfizer alleging breaches of the

GPs given a clean bill of health to engage in price setting
  • King & Wood Mallesons
  • Australia
  • March 18 2013

The ACCC has granted authorisation to individual General Practitioners (GPs) working in shared practices to allow them to engage in intra-practice

Australian antitrust enforcement focuses on healthcare & life sciences
  • Jones Day
  • Australia
  • December 22 2014

The Australian Competition and Consumer Commission (ACCC) has continued its focus on the healthcare and life sciences sectors this year, most

Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper

ACCC imposes strict transparency provisions on updated Medicines Australia Code of Conduct
  • King & Wood Mallesons
  • Australia
  • October 28 2014

Roll-out of a new edition of Medicines Australia’s Code of Conduct has struck a roadblock, with the ACCC requesting that Medicines Australia amend

Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its

Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the